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ABSTRACT
In this implementation phase of the European Cancer 
Patient’s Bill of Rights (BoR), we confirm the following 
three patient-centred principles that underpin this 
initiative:
1. The right of every European citizen to receive the most 
accurate information and to be proactively involved in 
his/her care.
2. The right of every European citizen to optimal and 
timely access to a diagnosis and to appropriate 
specialised care, underpinned by research and 
innovation.
3. The right of every European citizen to receive care in 
health systems that ensure the best possible cancer 
prevention, the earliest possible diagnosis of their 
cancer, improved outcomes, patient rehabilitation, 
best quality of life and affordable health care.
The key aspects of working towards implementing the BoR 
are:
 ► Agree our high-level goal. The vision of 70% long-
term survival for patients with cancer in 2035, 
promoting cancer prevention and cancer control and 
the associated progress in ensuring good patient 
experience and quality of life.
 ► Establish the major mechanisms to underpin its 
delivery. (1) The systematic and rigorous sharing 
of best practice between and across European 
cancer healthcare systems and (2) the active 
promotion of Research and Innovation focused 
on improving outcomes; (3) Improving access to 
new and established cancer care by sharing best 
practice in the development, approval, procurement 
and reimbursement of cancer diagnostic tests and 
treatments.
 ► Work with other organisations to bring into being a 
Europe based centre that will (1) systematically identify, 
evaluate and validate and disseminate best practice 
in cancer management for the different countries and 
regions and (2) promote Research and Innovation and its 
translation to maximise its impact to improve outcomes.
INTRODUCTION
Our growing knowledge of the funda-
mental biology of cancer and its treatment 
has resulted in radical improvements in 
outcomes for patients with cancer and an 
enhanced patient experience. Over half of 
all patients with cancer can expect long-term 
survival beyond 10 years after their diagnosis, 
and for most of these people the outcome is 
a cure. Good quality of life is now achievable 
for many patients on active therapy and for 
long-term survivors. However, patients with 
cancer, their carers and cancer professionals 
must work hard together to ensure that these 
benefits are shared by all and that the pace 
of progress is maintained and outcomes and 
patients’ experience continue to improve.
Despite the advances outlined above, cancer 
and the provision of cancer care still places a 
significant burden on Europe’s patients, citi-
zens and economies. As the population ages 
and if lifestyle-associated cancer risks such 
as smoking and obesity are not adequately 
addressed, then in many European countries 
more than half of the population will develop 
a cancer at some time in their lives.
Europe provides some of the best cancer 
care in the world and conducts high-quality, 
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Box 2 The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care
National Cancer Control Programmes (NCCPs) should develop cancer services which are patient centred, reflecting the views and needs of patients 
and their families. Access to reliable and comprehensive information about their disease, its treatment and the cancer care services available 
will empower patients to seek high-quality answers and choices for their care, which will in itself help to drive up the quality of services and the 
engagement of healthcare professionals and systems. Individuals may have different perceptions of their needs as compared with healthcare 
professionals. Good communication between healthcare professionals and patients will greatly improve care and enhance patient satisfaction. Shared 
decision making, involving a two-way transparent process between the healthcare providers and the European citizen, must be the overarching theme 
of this first principle.
European citizens should be managed through NCCPs, which seek to ensure:
 ► The right to access, if they so choose, all information regarding their state of health and to proactively participate in decision making regarding 
their treatment.
 ► Patient-focused information strategies that clearly state in a form and language that they can understand, their right to an optimal standard of care 
at all stages of their cancer journey.
 ► Information that their cancer unit or centre satisfies agreed optimal quality thresholds in relation to an appropriate degree of specialisation of cancer 
care.
 ► Transparency in access to all national anonymised data on treatments and clinical outcomes from healthcare institutions, cancer registries and 
independent audit programs, prior to the start of their treatment.
 ► A clear and transparent personalised care plan for their disease prior to the start of any treatment, with the right to a second opinion.
 ► Their privacy respected, with the level of confidentiality of their own data to be decided by the patient.
 ► Information on the research and innovation activities relevant to their cancer that are available locally, nationally and across Europe.
 ► Information on cancer survivorship and support services for post-treatment issues and a personalised survivorship care plan.
 ► Representation and support through patients' advocacy organisations that empower patients to be an equal partner in all areas that affect their 
health and well-being.
 ► The presence of a nominated member of the treatment team who can answer patient concerns and who can coordinate care on a patient’s behalf 
when necessary.
globally recognized cancer research. However, there are 
still significant disparities between European nations 
and regions in a number of key areas including: public 
information about cancer, accessing cancer care, deliv-
ering optimal treatment, supporting cancer survivorship 
and integrating cancer research and innovation across 
European countries. There are major disparities in the 
quality of cancer management and in the degree of 
expenditure. This results in unacceptable inequalities 
in cancer outcomes for European patients with cancer. 
In addition, costs of current treatments and long-term 
follow-up are placing significant economic burdens on 
European healthcare systems. Improvements in quality of 
care, translation of research discoveries and promotion 
of innovation will have to be achieved within affordable 
healthcare models.
The European Cancer Concord (ECC®), an equal 
partnership of Europe’s patients, patient advocates and 
leading cancer professionals, was formed to address these 
challenges.
The ECC seeks to catalyse change by working in an 
innovative, supportive and collaborative way with the 
many organisations which strive to improve cancer 
outcomes at the European and national level. To provide 
tangible benefits for European patients with cancer, 
the ECC created a ‘European Cancer Patient’s Bill of 
Rights’, a patient charter that underpins equitable access 
to optimal cancer control, cancer care and research for 
Europe’s citizens.1–3 This was launched at the European 
Parliament and endorsed by the European Union Health 
Commissioner on World Cancer Day (4 February 2014). 
Three patient-centred principles underpin the European 
Cancer Patient’s Bill of Rights (box 1):
The means of reducing cancer incidence are clearly 
available through increased public awareness and life-
style changes. Optimal organisation of the diagnostic 
approaches to identify cancer and precancerous condi-
tions as soon as possible will also improve outcomes and 
save lives. Timely access to specialised multidisciplinary 
treatment can result in long-term survival, greater than 10 
years, for a majority of patients; most of these patients are 
cured of their disease. In countries with the best diagnostic 
and clinical practice and excellent organisation of their 
cancer care, this long-term survival rate now approaches 
60% of patients. The skills that are essential to effectively 
monitor and support cancer survivors are being devel-
oped in many countries. A significant number of these 
advances have been mediated through the implemen-
tation of National Cancer Control Plans. Research and 
innovation for cancer has delivered improved diagnostic 
Box 1 The three patient-centred principles of the European 
Cancer Patient’s Bill of Rights
1. The right of every European citizen to receive the most accurate 
information and to be proactively involved in his/her care.
2. The right of every European citizen to optimal and timely access to 
a diagnosis and to appropriate specialised care, underpinned by 
research and innovation.
3. The right of every European citizen to receive care in health 
systems that ensure the best possible cancer prevention, the 
earliest possible diagnosis of their cancer, improved outcomes, 
patient rehabilitation, best quality of life and affordable healthcare.
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Box 3 The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, 
underpinned by research and innovation
Access to essential diagnostic and therapeutic cancer services must be the right of every European citizen, regardless of socioeconomic status, 
gender, age or nationality. Clear pathways of access to clinical innovation and associated research activities must inform all stages of the patient’s 
cancer journey. This second principle depends on equitable and transparent access to optimal cancer care.
European patients must be cared for in a system that ensures:
 ► Timely and well-organised access to validated diagnostics regardless of tumour type, with specialist second opinions in cases of doubt, to ensure 
accurate and earliest possible diagnosis of their cancer.
 ► Their diagnosis provided to them in an accurate and compassionate manner, by a specialist/experienced clinician.
 ► Timely access to an optimal quality of appropriately multidisciplinary specialised care, including relevant clinical research and innovation, to ensure 
best possible outcomes.
 ► Access to state-of-the-art care for each of the modalities of cancer treatment which underpin best practice including surgery, radiotherapy, 
chemotherapy and targeted therapy, immunotherapy and interventional radiology.
 ► All patients can benefit from the increasing precision in cancer diagnosis and treatment, which maximises the chance of benefits and reduces the 
risk of toxicity.
 ► Care delivered locally wherever possible and centralised where recommended by nationally or internationally approved guidelines and expert 
treatment recommendations.
 ► Access to appropriate psychological support at all stages of their cancer journey to deal with the impact of screening, diagnosis, treatment, quality 
of life and survivorship.
 ► The right to choice of location for diagnosis and treatment, even across national borders, moving their medical information as required to achieve 
this goal.
 ► Rapid access to the latest innovations in diagnosis and treatment for the individual patient with cancer following relevant regulatory approval.
 ► The right to access good quality care based on their need and not on their ability to pay for it.
 ► The right to expect research to be conducted on their particular cancer type and to be offered access to clinical studies where available and relevant 
to their condition.
 ► In the case of children and teenagers with cancer, the right to be treated in a specialised unit with an optimal standard of care, underpinned by 
research.
and treatment approaches and has doubled the long-
term survival of patients with cancer over the last three 
decades. Major improvements in the concepts and tech-
nologies of cancer discovery science in the last 10 years 
promise further diagnostic and therapeutic advances in 
the next two decades.
On World Cancer Day 2016, the ECC presented an 
updated version of the Bill of Rights (BoR) in Brussels 
and Strasbourg, recording progress and revealing a BoR 
Implementation Strategy. Successfully implementing the 
BoR will result in reduced cancer incidence and radically 
improved outcomes which will be demonstrated and 
measured in many ways. However, to demonstrate the 
scale of our ambitions, the ECC selected a specific goal.
 ► Improve the length and quality of patients’ survival. Our 
aim is to reach 70% survival beyond 10 years for all 
European citizens by 2035.
This 70:35 Vision will be addressed by three main mech-
anisms:
1. Identifying, evaluating, validating, sharing and 
implementing best practice in cancer diagnosis and care 
at national and regional levels in Europe. An actively 
managed, systematic approach to identifying and 
sharing best practice in cancer control and cancer 
care across European countries and regions is 
needed. We envisage that this will raise 10-year 
survival from an average of about 50% to around 
60%, which is already being achieved in some 
countries.
2. More intense research and innovation in discovery, 
translational, clinical and health-related cancer 
sciences. Sustaining and increasing the intensity of 
research and innovation and rapid translation of 
cancer research into practice is essential. Based 
on ongoing research, largely informed by existing 
concepts and technologies, this may provide a 
further increment in long-term survival towards or 
beyond 70% and improve both quality of life and 
the patient experience.
3. Improving access to new and established cancer care 
by sharing best practice in the development, approval, 
procurement and reimbursement of cancer diagnostic 
tests and treatments. There are many ways in which 
the experience of different countries may be 
shared to improve approaches to bringing new 
diagnostic tests and all treatment modalities 
(including chemotherapy, immunological therapy, 
radiotherapy and specialist surgery) into practice 
as quickly as possible and in an affordable and 
sustainable way.
This high-level selected goal of the 70:35 Vision has 
helped to focus discussions and served to communi-
cate our scale of ambition to improve cancer outcomes. 
However, it addresses only one aspect of the challenge 
we all face. Redoubling our efforts to prevent cancer 
through lifestyle changes and the application of our 
increasing scientific knowledge of the environmental 
and molecular causes of cancer, is critically important to 
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Box 4 The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the 
earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care
Cancer prevention and care at a national level must be organised in healthcare systems according to an integrated, efficiently budgeted National 
Cancer Control Programme (NCCP) that conforms to European guidelines and good international practice. The NCCP should develop a cancer centre/
cancer network/multidisciplinary team model that captures all aspects of cancer care, research and innovation, from diagnosis through treatment 
and rehabilitation, including patient survivorship and end-of-life care. A comprehensive and holistic approach, encompassing the entire cancer care 
continuum, must inform this third principle. Healthcare systems should recognise the socioeconomic inequality in cancer outcome and seek to 
minimise this at all points along the patient pathway.
European citizens and patients must be cared for in a system that ensures:
 ► Evidence-based public health interventions which can prevent cancer are a cornerstone of cancer control and include some of the most effective 
and affordable anticancer approaches.
 ► High-quality screening and diagnostic services delivered in a timely way must be accredited to ensure an optimal standard.
 ► NCCPs should be organised according to national guidance and regularly reviewed by external experts, including patient representatives and 
informed by pan-European guidance.
 ► As part of the NCCP, results should be audited to ensure optimal progress and benefit for the patients with cancer and the results of regular audits 
of outcomes should be used to inform service improvements.
 ► Cost-effective care should be provided at all stages of the cancer journey, from early diagnosis through treatment and supportive care. Appropriate 
use of health economic analyses can drive the improvement of effective and affordable care.
 ► The key issues of long-term follow-up and patient survivorship must be addressed to ensure best quality of life and personal fulfilment with 
active reintegration and participation in society and the work place. European citizens should have good access to comprehensive and continuous 
treatment for comorbidities, across the whole socioeconomic spectrum.
 ► Optimal pain and symptom management strategies must be in place for patients with cancer throughout their cancer journey.
 ► Sufficient expertise and experience in treating particular cancers in the patient’s healthcare institution is essential, including education and training 
for all healthcare and allied professionals involved in patient care.
 ► Patient advocacy organisations must be recognised as equal partners in all aspects of cancer control, cancer service developments, research and 
innovation.
 ► Specialised multidisciplinary teams must conform to national requirements, driven by recognised pan-European guidelines.
 ► Timely and transparent referral and follow-up between community healthcare/primary care professionals and cancer units or centres is essential, 
ensuring necessary treatment within an optimal and predetermined period of time.
 ► Cancer professionals must ensure that the patient is protected from harm caused by potentially poor-functioning health services, medical 
malpractice or errors.
reduce cancer incidence and mortality. Early diagnosis 
and prompt therapy are vitally important and depend on 
active engagement of primary and community healthcare 
services in improving cancer outcomes. Patients’ quality 
of life and the quality of the patient experience must be 
improved in parallel with improving survival, and this 
depends on effective, patient centred and integrated care 
provided by all the oncology professions, primary care, 
palliative care and the many other healthcare disciplines 
and professionals who diagnose and manage cancer 
patients in Europe.
The three key cancer patients’ rights
The three patient-centred principles which underpin 
the European Cancer Patient’s Bill of Rights are described 
in boxes 2–4.
THE WAY FORWARD
The ECC will interact closely with Europe’s many excel-
lent cancer organisations to catalyse the implementation 
of the BoR and improve cancer outcomes in Europe. All 
of these organisations have major contributions to make 
to the development of shared strategic plans and their 
implementation. The ECC will:
 ► Work with other organisations to advocate a formal 
sustained strategic Europe-wide approach to 
improve cancer control and outcomes, based on 
identifying, evaluating and sharing good practice 
between countries and regions;
 ► Collaborate with and support other organisations 
at European and national levels to advance cancer 
control and research;
 ► Deliver evidence-based papers to inform 
improvements in cancer care;
 ► Initiate specific workstreams, in collaboration with 
other cancer organisations, to identify, disseminate 
and support the implementation of new approaches 
to improve patient outcomes.
The key aspects in the next 2 years, of our work towards 
implementing the BoR are (box 5):
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Box 5 The next steps for the Bill of Rights
 ► Agree our high level goal. The 70:35 vision: Achieving 70% long-term survival for patients with cancer by 2035, promoting cancer prevention and 
cancer control and the associated progress in ensuring good patient experience and quality of life.
 ► Establish the major mechanisms to underpin delivery of the 70:35 vision. (1) The systematic and rigorous sharing of best practice between and 
across European cancer healthcare systems; (2) the active promotion of Research and Innovation focused on improving outcomes; (3) improving 
access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer 
diagnostic tests and treatments.
 ► Work with other organisations to bring into being a Europe-based centre, which will (1) systematically identify, evaluate and validate and disseminate 
best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise 
its impact to improve outcomes.
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